{
    "clinical_study": {
        "@rank": "28416", 
        "acronym": "ECLIPSE", 
        "arm_group": {
            "arm_group_label": "ranibizumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare\n      VEGF driven ocular diseases."
        }, 
        "brief_title": "An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Choroidal Neovascularization", 
            "Macular Edema", 
            "Glaucoma, Neovascular", 
            "Diabetic Retinopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Retinopathy", 
                "Edema", 
                "Glaucoma", 
                "Glaucoma, Neovascular", 
                "Macular Edema", 
                "Neovascularization, Pathologic", 
                "Retinal Diseases", 
                "Choroidal Neovascularization"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Active choroidal neovascularization (CNV)\n\n          -  Active macular edema (ME)\n\n          -  Rubeosis iridis/neovascular glaucoma.\n\n          -  Proliferative diabetic retinopathy requiring vitrectomy.\n\n        Exclusion Criteria:\n\n          -  wet Age-related macular degeneration\n\n          -  pathologic myopia\n\n          -  pseudoxanthoma elasticum\n\n          -  diabetic macular edema\n\n          -  retinal vein occlusion\n\n          -  < 18 years of age\n\n          -  History of hypersensitivity to ranibizumab\n\n          -  Use of any systemic anti-angiogenic drugs 3 months before inclusion\n\n          -  Women of child-bearing potential and Pregnant or nursing (lactating) women.\n\n          -  Active or suspected ocular infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908816", 
            "org_study_id": "CRFB002GFR02"
        }, 
        "intervention": {
            "arm_group_label": "ranibizumab", 
            "description": "One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)", 
            "intervention_name": "ranibizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49044"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lagord", 
                        "country": "France", 
                        "zip": "17140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melun", 
                        "country": "France", 
                        "zip": "77000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montauban", 
                        "country": "France", 
                        "zip": "82000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes Cedex 1", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75007"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitnt Herblain", 
                        "country": "France", 
                        "zip": "44819"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31077"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vannes", 
                        "country": "France", 
                        "zip": "56000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate and severity of serious and non-serious, ocular and non-ocular adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908816"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "BCVA will be tested using the ETDRS, the Snellen or Monoyer scales. VA measurements will be preferentially taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score will be calculated using the BCVA worksheet which will be kept in the source data and the score will be recorded in the eCRF. ETDRS, Snellen and Monoyer VA measurements will be transformed in logMAR to be analyzed.", 
                "measure": "Average change of BCVA for patients with CNV and ME", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Change of the extent of iris neovascularization using \"Teich and Walsh grading system\" using iris photography", 
                "measure": "Average change of neovascularization extension for patients with neovascular glaucoma", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Occurrence of postoperative vitreous cavity hemorrhage", 
                "measure": "Proportion of patient with Vitreous Cavity Hemorrhage occurrence for patient with proliferative retinopathy", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}